Literature DB >> 19269969

Silencing of D4-GDI inhibits growth and invasive behavior in MDA-MB-231 cells by activation of Rac-dependent p38 and JNK signaling.

Yaqin Zhang1, Leslie A Rivera Rosado, Sun Young Moon, Baolin Zhang.   

Abstract

The Rho GDP dissociation inhibitor D4-GDI is overexpressed in some human breast cancer cell lines (Zhang, Y., and Zhang, B. (2006) Cancer Res. 66, 5592-5598). Here, we show that silencing of D4-GDI by RNA interference abrogates tumor growth and lung metastasis of otherwise highly invasive MDA-MB-231 breast cancer cells. Under anchorage-independent culture conditions, D4-GDI-depleted cells undergo rapid apoptosis (anoikis), which is known to hinder metastasis. We also found that D4-GDI associates with Rac1 and Rac3 in breast cancer cells, but not with other Rho GTPases tested (Cdc42, RhoA, RhoC, and TC10). Silencing of D4-GDI results in constitutive Rac1 activation and translocation from the cytosol to cellular membrane compartments and in sustained activation of p38 and JNK kinases. Rac1 blockade inhibits p38/JNK kinase activities and the spontaneous anoikis of D4-GDI knockdown cells. These results suggest that D4-GDI regulates cell function by interacting primarily with Rac GTPases and may play an integral role in breast cancer tumorigenesis. D4-GDI could prove to be a potential new target for therapeutic intervention.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19269969      PMCID: PMC2676027          DOI: 10.1074/jbc.M807845200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  60 in total

1.  Apoptosis induced by Rac GTPase correlates with induction of FasL and ceramides production.

Authors:  N Embade; P F Valerón; S Aznar; E López-Collazo; J C Lacal
Journal:  Mol Biol Cell       Date:  2000-12       Impact factor: 4.138

2.  Endogenous, hyperactive Rac3 controls proliferation of breast cancer cells by a p21-activated kinase-dependent pathway.

Authors:  J P Mira; V Benard; J Groffen; L C Sanders; U G Knaus
Journal:  Proc Natl Acad Sci U S A       Date:  2000-01-04       Impact factor: 11.205

3.  RhoC GTPase, a novel transforming oncogene for human mammary epithelial cells that partially recapitulates the inflammatory breast cancer phenotype.

Authors:  K L van Golen; Z F Wu; X T Qiao; L W Bao; S D Merajver
Journal:  Cancer Res       Date:  2000-10-15       Impact factor: 12.701

4.  Molecular portraits of human breast tumours.

Authors:  C M Perou; T Sørlie; M B Eisen; M van de Rijn; S S Jeffrey; C A Rees; J R Pollack; D T Ross; H Johnsen; L A Akslen; O Fluge; A Pergamenschikov; C Williams; S X Zhu; P E Lønning; A L Børresen-Dale; P O Brown; D Botstein
Journal:  Nature       Date:  2000-08-17       Impact factor: 49.962

5.  The Syk tyrosine kinase suppresses malignant growth of human breast cancer cells.

Authors:  P J Coopman; M T Do; M Barth; E T Bowden; A J Hayes; E Basyuk; J K Blancato; P R Vezza; S W McLeskey; P H Mangeat; S C Mueller
Journal:  Nature       Date:  2000-08-17       Impact factor: 49.962

6.  LyGDI functions in cancer metastasis by anchoring Rho proteins to the cell membrane.

Authors:  Takahide Ota; Masayo Maeda; Shiho Suto; Masaaki Tatsuka
Journal:  Mol Carcinog       Date:  2004-04       Impact factor: 4.784

7.  SATB1 reprogrammes gene expression to promote breast tumour growth and metastasis.

Authors:  Hye-Jung Han; Jose Russo; Yoshinori Kohwi; Terumi Kohwi-Shigematsu
Journal:  Nature       Date:  2008-03-13       Impact factor: 49.962

Review 8.  Rho proteins and cancer.

Authors:  Anne J Ridley
Journal:  Breast Cancer Res Treat       Date:  2004-03       Impact factor: 4.872

9.  Sustained activation of JNK/p38 MAPK pathways in response to cisplatin leads to Fas ligand induction and cell death in ovarian carcinoma cells.

Authors:  Abdellah Mansouri; Lon D Ridgway; Anita L Korapati; Qingxiu Zhang; Ling Tian; Yibin Wang; Zahid H Siddik; Gordon B Mills; François X Claret
Journal:  J Biol Chem       Date:  2003-03-12       Impact factor: 5.157

10.  Prognostic value of rho GTPases and rho guanine nucleotide dissociation inhibitors in human breast cancers.

Authors:  Wen G Jiang; Gareth Watkins; Jane Lane; Giles H Cunnick; Anthony Douglas-Jones; Kefah Mokbel; Robert E Mansel
Journal:  Clin Cancer Res       Date:  2003-12-15       Impact factor: 12.531

View more
  27 in total

1.  RhoGDI2 antagonizes ovarian carcinoma growth, invasion and metastasis.

Authors:  Ellen V Stevens; Natalie Banet; Cercina Onesto; Ana Plachco; Jamie K Alan; Nana Nikolaishvili-Feinberg; Bentley R Midkiff; Pei Fen Kuan; Jinsong Liu; C Ryan Miller; Dominico Vigil; Lee M Graves; Channing J Der
Journal:  Small GTPases       Date:  2011-07-01

Review 2.  Small Rho GTPases in the control of cell shape and mobility.

Authors:  Arun Murali; Krishnaraj Rajalingam
Journal:  Cell Mol Life Sci       Date:  2013-11-26       Impact factor: 9.261

Review 3.  Disrupting P-glycoprotein function in clinical settings: what can we learn from the fundamental aspects of this transporter?

Authors:  Francisco S Chung; Jayson S Santiago; Miguel Francisco M De Jesus; Camille V Trinidad; Melvin Floyd E See
Journal:  Am J Cancer Res       Date:  2016-08-01       Impact factor: 6.166

Review 4.  Pleiotropic functions of Rho GTPase signaling: a Trojan horse or Achilles' heel for breast cancer treatment?

Authors:  P R McHenry; T Vargo-Gogola
Journal:  Curr Drug Targets       Date:  2010-09       Impact factor: 3.465

Review 5.  Metastasis suppressor genes at the interface between the environment and tumor cell growth.

Authors:  Douglas R Hurst; Danny R Welch
Journal:  Int Rev Cell Mol Biol       Date:  2011       Impact factor: 6.813

6.  RhoGDI2 induced malignant phenotypes of pancreatic cancer cells via regulating Snail expression.

Authors:  Bin Yi; You Hu; Dongming Zhu; Jun Yao; Jian Zhou; Yi Zhang; Zhilong He; Lifeng Zhang; Zixiang Zhang; Jian Yang; Yuchen Tang; Yujie Huang; Dechun Li; Qiuhua Liu
Journal:  Genes Genomics       Date:  2022-02-11       Impact factor: 1.839

7.  RhoGDI2 confers resistance to 5-fluorouracil in human gastric cancer cells.

Authors:  Zhong Zheng; Xiang-Yi He; Jian-Fang Li; Bei-Qin Yu; Xue-Hua Chen; Jun Ji; Jia-Nian Zhang; Qin-Long Gu; Zheng-Gang Zhu; Bing-Ya Liu
Journal:  Oncol Lett       Date:  2012-10-01       Impact factor: 2.967

8.  ZIP4 Increases Expression of Transcription Factor ZEB1 to Promote Integrin α3β1 Signaling and Inhibit Expression of the Gemcitabine Transporter ENT1 in Pancreatic Cancer Cells.

Authors:  Mingyang Liu; Yuqing Zhang; Jingxuan Yang; Xiaobo Cui; Zhijun Zhou; Hanxiang Zhan; Kai Ding; Xiang Tian; Zhibo Yang; Kar-Ming A Fung; Barish H Edil; Russell G Postier; Michael S Bronze; Martin E Fernandez-Zapico; Marc P Stemmler; Thomas Brabletz; Yi-Ping Li; Courtney W Houchen; Min Li
Journal:  Gastroenterology       Date:  2019-11-09       Impact factor: 22.682

9.  Rictor regulates cell migration by suppressing RhoGDI2.

Authors:  N K Agarwal; C-H Chen; H Cho; D R Boulbès; E Spooner; D D Sarbassov
Journal:  Oncogene       Date:  2012-07-09       Impact factor: 9.867

10.  Centrosomal localization of RhoGDIβ and its relevance to mitotic processes in cancer cells.

Authors:  Yong-Sheng Jiang; Masayo Maeda; Mayumi Okamoto; Mikiko Fujii; Ryuichiro Fukutomi; Masato Hori; Masaaki Tatsuka; Takahide Ota
Journal:  Int J Oncol       Date:  2012-12-07       Impact factor: 5.650

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.